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ABSTRACT 50 
Objective Earlier studies on antibiotics exposure and development of inflammatory bowel 51 
disease (IBD, Crohn’s disease and ulcerative colitis) may have been biased by familial factors 52 
and gastroenteritis. We aimed to estimate the association between antibiotics during pregnancy or 53 
infantile age and very early onset (VEO-) IBD.  54 
Design In this cohort study of 827 239 children born in Sweden 2006-2013, we examined the link 55 
between exposure to systemic antibiotics and VEO-IBD (diagnosis <6 years of age), using Cox 56 
proportional hazard regression models. Information on antibiotics and IBD was retrieved from 57 
the nationwide population-based Swedish Prescribed Drug Register and the National Patient 58 
Register. We specifically examined potential confounding from parental IBD and gastroenteritis. 59 
Results Children exposed to antibiotics during pregnancy were at increased risk of IBD 60 
compared to general population controls (adjusted hazard ratio (aHR) 1.93; 95% confidence 61 
interval (CI) 1.06-3.50). Corresponding aHRs were 2.48 (1.01-6.08) for Crohn’s disease (CD) 62 
and 1.25 (0.47-3.26) for ulcerative colitis (UC) respectively. For antibiotics in infantile age, the 63 
aHR for IBD was 1.11 (0.57-2.15); for CD 0.72 (0.27-1.92) and 1.23 (0.45-3.39) for UC. 64 
Excluding children with gastroenteritis 12 months prior to the first IBD diagnosis retained similar 65 
aHR for antibiotics during pregnancy and CD, while the association no longer remained 66 
significant for IBD. 67 
Conclusion We found that exposure to antibiotics during pregnancy, but not in infantile age, is 68 
associated with an increased risk of VEO-IBD regardless of gastroenteritis. The risk increase for 69 
exposure in pregnancy may be due to changes in the microbiota. 70 
71 
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Summary “box” 72 
What is already known about this subject? Very early onset (VEO-) inflammatory bowel 73 
disease (IBD) has gradually become more common. One potential risk factor for VEO-IBD is 74 
antibiotic exposure during pregnancy and in infantile age.  75 
What are the new findings? In this population-based study of more than 800 000 children, we 76 
found a positive association between antibiotics exposure during pregnancy, but not in infantile 77 
age, and later VEO-IBD.   78 
How might it impact on clinical practice in the foreseeable future? The risk increase for 79 
exposure in pregnancy may be due to changes in the microbiota, which could have an impact on 80 
care of pregnant women. However, the absolute risk of disease was very low, and antibiotics 81 
during pregnancy should still be used when needed.  82 
83 
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INTRODUCTION 84 
Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), 85 
is characterized by chronic inflammation of the gastrointestinal tract. Symptoms related to the 86 
disease include diarrhoea, rectal bleeding, abdominal pain and weight loss. Although children 87 
(diagnosed at <18 years of age) may present with these classical symptoms, non-specific 88 
symptoms such as growth failure, anaemia and other extra-intestinal manifestations are also 89 
common manifestations of paediatric IBD.
1
 Interestingly, patients with very early onset (VEO)-90 
IBD (defined as diagnosed before six years of age) seem to represent a specific entity, possibly 91 
more likely to present with rectal bleeding due to a colonic phenotype (in CD)
2
 and a family 92 
history of IBD.
2-5
 This disease entity has gradually become more common and recent data 93 
suggest that the increase in IBD incidence is more pronounced in patients with VEO-IBD than 94 
among children ≥6 years old, although the overall numbers are still very small compared to 95 
young adults.
6
  96 
The pathogenesis is characterized by a complex interaction between genetics, an 97 
aberrant mucosal immune response to gut microbiota, disruption of gut barrier, and 98 
environmental triggers. While genetic factors clearly play an important role in the etiology of 99 
IBD,
7-10
 they cannot explain the recent rise in disease incidence or the proband concordance rate 100 
of 38-62% in monozygotic twins with CD (even less in UC).
11 12
 This has encouraged a search for 101 
environmental factors and led to the identification of factors such as smoking, oral contraceptives 102 
and appendectomy due to appendicitis (data on appendectomy have however been 103 
contradictory)
13
 as potential risk factors in adulthood IBD while less is known for childhood 104 
IBD.
14-19
  105 
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To what extent pathophysiologic mechanism of IBD can be applied to VEO-IBD 106 
remains partly unknown. It has been proposed that the influence of genetics might be more 107 
pronounced in VEO-IBD, due to the effect of rare variants with a high penetrance for IBD.
20
 108 
However, the role of environmental risk factors in VEO-IBD is largely unknown.  109 
One potential risk factor for VEO-IBD is antibiotic exposure during pregnancy and 110 
in infantile age. Ungaro et al. reported an increased risk of IBD following antibiotic exposure, 111 
especially in children, in a recent meta-analysis of eleven observational studies.
21
 The association 112 
was limited to individuals with newly onset CD and not seen for UC. Some earlier studies have 113 
also found a positive dose-response relationship between antibiotics exposure and later IBD, but 114 
whether this also applies to VEO-IBD remains unknown.  115 
Therefore, we aimed to estimate the association between antibiotics during 116 
pregnancy or infantile age and VEO-IBD (CD and UC), while adjusting for parental IBD, as well 117 
as taking gastroenteritis and number of doses into account in a population-based study.  118 
 119 
 120 
 121 
 122 
 123 
 124 
125 
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METHOD 126 
Study population and register linkage 127 
This nationwide prospective population-based register study included all children born January 128 
2006 to December 2013, identified together with their mothers from the Swedish Medical Birth 129 
Register (MBR). Fathers to the children were identified through the Swedish Multi-generation 130 
Register.
22
 We used the Swedish Prescribed Drug Register (SPDR)
23
 and the National Patient 131 
Register (NPR)
24
 to retrieve data on exposure and outcome. The SPDR contains complete data on 132 
all dispensed drugs from pharmacies since July 2005 while the NPR began in 1964, became 133 
nationwide in 1987 (inpatient diagnoses only), and added hospital-based outpatient visit data in 134 
2001. Data from the different registers were linked using the unique personal identity number 135 
assigned to all residents in Sweden.
25
 136 
Variables 137 
Antibiotic exposure was defined as filled prescriptions of relevant ATC codes (Anatomical 138 
Therapeutic Chemical): J01A-J01X (systemic antibiotics), and were obtained through the SPDR. 139 
We categorised antibiotics into two groups: “systemic antibiotics” which included any type of 140 
antibiotics; and “PcV” (Phenoxymethylpenicillin), which is by far the most commonly prescribed 141 
type of antibiotic in Sweden both during pregnancy and in childhood.
26
 142 
Our outcome IBD was defined as having ≥ 2 diagnoses of either CD or UC 143 
according to relevant International Classification of Disease (ICD)-10 codes K50 and K51 144 
respectively recorded in the NPR, with onset before 6 years of age. Crohn’s disease was defined 145 
as ≥ 2 CD diagnoses but never an ulcerative colitis diagnosis and UC was defined as ≥ 2 UC 146 
diagnoses but never a CD diagnosis. These outcome definitions have previously been validated 147 
by Jakobsson et al. who found a positive predictive value (PPV) of 93% (95% CI: 87–97) for 148 
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IBD, 90% (77–97) for UC and 81% (67–91) for CD, when compared to the Copenhagen 149 
criteria.
27
 While IBD-unclassified is now regarded as a separate entity (and some data suggests 150 
that it may represent up to 20% of the total pediatric IBD population),
28
 this paper focused on CD 151 
and UC. 152 
Co-variates; Through the MBR we retrieved information on the child’s date of 153 
birth, sex, gestational age (days), mode of delivery (vaginal or caesarean section), maternal 154 
smoking at first visit to the antenatal care clinic (yes/no), maternal age at delivery (≤19, 20-24, 155 
25-29, 30-34, or ≥35 years), and parity (child’s birth order at current delivery; first-born (1) or not 156 
(≥2)). Data from Cnattingius et al. suggest a high quality of data in the MBR with a coverage of 157 
>98% of all births in Sweden.
29
  158 
Maternal and paternal IBD was defined from the NPR similarly to that of the 159 
children (two records of either: ICD-8: 563.00, 563.10, 569.02; ICD-9: 555, and ICD-10: K50 for 160 
CD; and ICD-8: 563.98, 563.99; ICD-9: 556, and ICD-10: K51 for UC). Information on highest 161 
level of education of either parent (0-12 vs >12 years) was identified through the Longitudinal 162 
integration database for health insurance and labour market studies and parents’ country of birth 163 
(Sweden or other) was identified from the Total Population Register (TPR).  164 
We defined the beginning of the pregnancy (conception date) as date of birth minus 165 
gestational age in days. We furthermore divided pregnancy duration into trimester 1 (day 1-91), 2 166 
(day 92-189), and 3 (day 190+) to examine time-varying effects of fetal antibiotics exposure. To 167 
ensure that the full pregnancy would be covered by this study (especially antibiotics exposure in 168 
the first trimester in offspring born close to the starting point of the SPDR), we restricted our 169 
study population to children with estimated conception date as on or after July 1
st
, 2005. 170 
Information on migration and death was obtained from the TPR to be able to define end of 171 
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follow-up. Offspring to women who immigrated to Sweden during pregnancy were excluded 172 
from the study (n=14 030).  173 
 174 
Statistical analysis 175 
The risk of IBD, and CD and UC separately, in children exposed to antibiotics during pregnancy 176 
and in infantile age compared to unexposed children, was examined in Cox proportional hazard 177 
models. Attained age was used as the underlying time scale and clustering within families was 178 
taken into account by using a sandwich estimator for the standard errors. Follow-up ended with 179 
first IBD diagnosis, emigration, death or end of study period (December 31
st
, 2014 i.e at least one 180 
year of follow-up), whichever happened first. The proportional hazards assumption was tested 181 
using Schoenfeld’s residuals (p-values of 0.58 for exposure during pregnancy and 0.84 for 182 
exposure in infantile age). Antibiotic exposure during pregnancy was regarded as exposed or non-183 
exposed at the start of follow-up, while exposure after birth was modelled as a time(age)-varying 184 
exposure, i.e. a model in which all individuals start as unexposed and then the exposure status 185 
changes at the time an individual becomes exposed. However, as there was no sign of non-186 
proportional hazards we did not allow for the effect of the exposure to vary over time.  187 
Potential confounders were identified based on the Directed Acyclic Graphs (DAG) 188 
concept,
30
 and the final models were adjusted for: mother’s and father’s history of IBD, parental 189 
education, mother’s and father’s country of birth (in analyses of exposure during pregnancy and 190 
in childhood) and mode of delivery (in analysis of exposure in infantile age) as shown in Figure 191 
1. Those with missing information on these variables were excluded (n=2848 for exposure in 192 
pregnancy and n=3274 for exposure in infantile age) and complete case analyses were performed. 193 
Crude and adjusted Hazard Ratios (HR) are presented. 194 
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Additional analyses: Sensitivity analyses were performed by excluding all 195 
individuals who had been diagnosed with gastroenteritis, either bacterial or viral, according to 196 
ICD 10 codes A00-A09, within 12 months prior to onset of their first IBD diagnosis. The risk of 197 
IBD with onset after 2 years of age in children exposed to systemic antibiotics in the first year of 198 
life, was further tested to investigate potential information bias such as misclassification or 199 
reverse causation. This since a possible misclassification of first occurrence of IBD symptoms as 200 
gastroenteritis, treated with antibiotics, may induce an association between antibiotics and IBD. 201 
A potential dose-relationship between number of antibiotics prescriptions in childhood (1, 2 or ≥3 202 
as a continuous variable) and IBD was tested. Dispensed prescriptions of the same type of 203 
antibiotics within 7 days from the prior dispense was counted as one dispense. Too few women 204 
had filled more than one prescription of antibiotics during pregnancy to be able to perform dose-205 
response-analyses. The role of timing of systemic antibiotics exposure during the fetal period (1
st
 206 
vs 2
nd
 vs 3
rd
 trimester) and IBD was further explored. We also examined if the risk increase by 207 
antibiotic exposure was dependent on parity by adding interaction terms between parity (first-208 
born vs. non-first born) and antibiotic exposure.  209 
STATA statistical software (version 14) was used for all statistical analyses. 210 
The study was approved by the Regional Ethical Review board in Stockholm, Sweden.  211 
 212 
213 
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RESULTS 214 
The final study population consisted of 827 239 children (Figure 2). Some 12 606 children 215 
emigrated during follow-up, and another 2428 died.  216 
Overall, 17% (n=140 665) of the children had been exposed to antibiotics during 217 
pregnancy, and 5% (n=40 116) had been exposed on two or more occasions. In infantile age, 65% 218 
(n=539 809) had been exposed to systemic antibiotics at least once, and 373 802 (70% of those 219 
exposed at all) had filled two or more prescriptions (Table 1).  220 
221 
 12 
 
Table 1. Descriptive table of the study population. 222 
 All IBD CD UC 
 N % n % n % n % 
Variable 827 239 100.0 51 100.0 20 100.0 24 100.0 
Sex         
  Males 425 212 51.4 26 51.0 12 60.0 11 45.8 
  Females 402 027 48.6 25 49.0 8 40.0 13 54.2 
Systemic antibiotic exposure during 
pregnancy  
140 665 17.0 15 29.4 7 35.0 5 20.8 
  Phenoxymethylpenicillin (PcV) 60 701 7.3 8 15.7 4 20.0 3 12.5 
  Pivmecillinam 34 264 4.1 2 3.9 1 5.0 1 4.2 
  Nitrofurantoin 30 904 3.7 4 7.8 1 5.0 2 8.3 
 Other 42 672 5.2 5 9.8 4 20.0 0 0 
Number of prescriptions during 
pregnancy (any)* 
        
  1 100 549 12.2 10 19.6 4 20.0 3 12.5 
  2 26 357 3.2 3 5.9 2 10.0 1 4.2 
  ≥3 13 759 1.7 2 3.9 1 5.0 1 4.2 
Systemic antibiotic exposure in 
infantile age  
539 809 65.3 43 84.3 16 80.0 20 83.3 
 Phenoxymethylpenicillin (PcV) 460 283 55.6 38 74.5 14 70.0 17 70.8 
 Amoxicillin 152 052 18.4 15 29.4 7 35.0 5 20.8 
 Flucloxacillin 80 814 9.8 13 25.5 5 25.0 4 16.7 
 Other 204 387 24.7 28 54.9 10 50.0 11 45.8 
Number of prescriptions in infantile 
age (any)* 
        
  1 166 007 20.1 3 5.9 1 5.0 2 8.3 
  2 111 761 13.5 8 15.7 2 10.0 6 25.0 
  ≥3 262 041 31.7 32 62.7 13 65.0 12 50.0 
Mothers’ diagnoses          
  IBD 6 780 0.8 7 13.7 4 20.0 2 8.3 
  CD 1 943 0.2 2 3.9 2 10.0 0 0.0 
  UC 3 598 0.4 5 9.8 2 10.0 2 8.3 
Fathers’ diagnoses         
  IBD 7 333 0.9 4 7.8 0 0.0 2 8.3 
  CD 1 868 0.2 0 0.0 0 0.0 0 0.0 
  UC 3 972 0.5 1 2.0 0 0.0 0 0.0 
Parents’ highest achieved education         
  0-12 years 337 312 40.8 18 35.3 8 40.0 7 29.2 
  >12 years 485 926 58.7 33 64.7 12 60.0 17 70.8 
  Missing 4 001 0.5 0 0.0 0 0.0 0 0.0 
Mother’s country of birth         
  Sweden 646 032 78.1 42 82.4 18 90.0 20 83.3 
  Other 181 207 21.9 9 17.7 2 10.0 4 16.7 
Father’s country of birth         
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 223 
Any – Any type of systemic antibiotics (ATC: J01) 224 
* Independent on time in relation to diagnosis (i.e. either before or after onset of diagnosis) 225 
“Other” antibiotics during pregnancy – Tetracyclines (J01A), penicillins with extended spectrum 226 
(J01CA) (except pivmecillinam), beta-lactamase sensitive penicillins (J01CE) (except 227 
phenoxymethylpenicillin), beta-lactamase resistant penicillins (J01CF), combinations of 228 
penicillins, incl. beta-lactamase inhibitors (J01CR), cephalosporins (J01DB-DD), monobactams 229 
(J01DF), carbapenems (J01DH), trimethoprim (J01EA), combinations of sulfonamides and 230 
trimethoprim (J01EE), macrolides (J01FA), lincosamides (J01FF), other aminoglycosides 231 
(J01GB), fluoroquinolones (J01MA), other antibacterials (J01X) (except nitrofurantoin). 232 
“Other” antibiotics during childhood – Tetracyclines (J01A), penicillins with extended spectrum 233 
(J01CA) (except amimoxicillin), beta-lactamase resistant penicillins (J01CF) (except 234 
flucloxacillin), combinations of penicillins, incl. beta-lactamase inhibitors (J01CR), 235 
cephalosporins (J01DB-DE), monobactams (J01DF), carbapenems (J01DH), trimethoprim 236 
(J01EA), combinations of sulfonamides and trimethoprim (J01EE), macrolides (J01FA), 237 
lincosamides (J01FF), other aminoglycosides (J01GB), fluoroquinolones (J01MA), other 238 
antibacterials (J01X). 239 
240 
  Sweden 630 372 76.2 39 76.5 18 90.0 19 79.2 
  Other 178 669 21.6 12 23.5 2 10.0 5 20.8 
  Missing 18 198 2.2 0 0.0 0 0.0 0 0.0 
Mode of delivery         
  Vaginal 679 693 82.2 43 84.3 16 80.0 20 83.3 
  Caesarean Section 147 107 17.8 8 15.7 4 20.0 4 16.7 
  Missing 439 0.1 0 0.0 0 0.0 0 0.0 
Maternal smoking at first visit to the 
antenatal care clinic  
        
  Yes 51 892 6.3 3 5.9 1 5.0 1 4.2 
  No 741 727 89.7 46 90.2 17 85.0 23 95.8 
  Missing 33 620 4.1 2 3.9 2 10.0 0 0.0 
Maternal age at delivery (years)         
  ≤19 12 060 1.5 0 0.0 0 0.0 0 0.0 
 20-24 105 879 12.8 4 7.8 2 10.0 1 4.2 
 25-29 237 650 28.7 18 35.3 7 35.0 7 29.2 
 30-34 287 319 34.7 18 35.3 5 25.0 12 50.0 
  ≥35 184 330 22.3 11 21.6 6 30.0 4 16.7 
  Missing 1 0.0 0 0.0 0 0.0 0 0.0 
Parity (at current delivery)         
  1 361 332 43.7 26 51.0 11 55.0 10 41.7 
  ≥2 465 907 56.3 25 49.0 9 45.0 14 58.3 
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The median time from conception to exposure to systemic antibiotics was 125 days 241 
(interquartile range (IQR) 64-197 days), while the median age at first exposure to systemic 242 
antibiotics in childhood was 1.3 years (IQR 0.8-2.1 years). 243 
In total, 51 children with IBD (CD and/or UC), 20 with CD (but never an UC 244 
diagnosis) and 24 with UC (but never a CD diagnosis) could be identified through the NPR. 245 
Approximately 14% of the children with IBD had a mother with IBD and 8% had a father with 246 
IBD, compared to those children without IBD, where the corresponding numbers for parental 247 
IBD were less than 1% (0.8% mothers and 0.9% fathers) (Table 1). The median age of the first 248 
IBD diagnosis was 2.0 years (IQR 0.9-4.1 years). 249 
Antibiotics during pregnancy 250 
Table 2 presents crude and adjusted Hazard Ratios (aHR) and 95% Confidence Intervals (CI) for 251 
the association between exposure to antibiotics during pregnancy and IBD, CD and UC 252 
respectively. There was a 93% significantly increased risk of IBD in children exposed to systemic 253 
antibiotics during pregnancy (aHR1.93, 95% CI 1.06-3.50). An association remained for CD 254 
(aHR 2.48, 95% CI 1.01-6.08), but not for UC (aHR 1.25, 95% CI 0.47-3.26). The aHR seemed 255 
to remain when restricting systemic antibiotic exposure to PcV (aHR for IBD 2.15, 95% CI 1.02-256 
4.56), although no longer significant for CD (aHR 2.85, 95% CI 0.96-8.45). . Still, no significant 257 
association was found between “PcV” and UC.  258 
In total, six children had been diagnosed with gastroenteritis 12 months prior to the 259 
first diagnosis of IBD, where five had been diagnosed with a viral or unspecified gastroenteritis 260 
and colitis (ICD 10: A09) and one had been diagnosed with a bacterial gastroenteritis with 261 
Clostridium difficile (ICD 10: A047). In sensitivity analyses, excluding these individuals, similar 262 
aHR remained for systemic antibiotics and CD (aHR 2.51, 95% CI 0.96-6.56), although no longer 263 
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significant, and with lower non-significant risk estimates for systemic antibiotics and IBD (aHR 264 
1.68, 95% CI 0.88-3.21) (Table 2).265 
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Table 2. Crude and adjusted Hazard ratios and 95% confidence intervals for inflammatory bowel disease (IBD) in relation to exposure 266 
to systemic antibiotics and “PcV” during pregnancy, and results from sensitivity analysis excluding those who have been diagnosed 267 
with gastroenteritis (GE) 12 months prior to onset of the first IBD diagnosis.  268 
 269 
cHR – Crude Hazard Ratio; 3 945 000 Person-years  270 
aHR – Adjusted Hazard Ratio; 3 874 000 Person-years; analyses adjusted for mother’s and father’s history of IBD, parental education, 271 
mother’s and father’s country of birth. Those with missing information on these variables are excluded (no cases excluded). 272 
n – cases, i.e. those who have been exposed to antibiotics prior to onset of IBD/UC/CD diagnosis 273 
exl.GE – excluding gastroenteritis, either bacterial or viral, according to ICD 10 codes A00-A09 12 months prior to onset of the first 274 
IBD diagnosis. 275 
PcV – Phenoxymethylpenicillin 276 
 IBD  Crohn’s disease (CD)  Ulcerative colitis (UC) 
Antibiotics n cHR (95% CI) aHR (95% CI) n cHR (95% CI) aHR (95% CI) n cHR (95% CI) aHR (95% CI) 
Any 15 1.96  
(1.07-3.57) 
1.93  
(1.06-3.50) 
7 2.52  
(1.01-6.28) 
2.48 
(1.01-6.08) 
5 1.24  
(0.47-3.32) 
1.25  
(0.47-3.26) 
  exl.GE 12 1.70  
(0.88-3.29) 
1.68  
(0.88-3.21) 
6 2.55  
(0.95-6.86) 
2.51 
(0.96-6.56) 
4 1.05 
(0.36-3.08) 
1.05 
(0.36-3.08) 
PcV 8 2.19  
(1.03-4.66) 
2.15  
(1.02-4.56) 
4 2.92 
(0.99-8.67) 
2.85 
(0.96-8.45) 
3 1.71  
(0.51-5.71) 
1.68  
(0.51-5.97) 
  exl.GE 7  2.17  
(0.97-4.84) 
2.13  
(0.96-4.75) 
3 2.50 
(0.73-8.62) 
2.45  
(0.71-8.42) 
3 1.87  
(0.56-6.34) 
1.85  
(0.55-6.21) 
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The role of timing of systemic antibiotics exposure during pregnancy and IBD was 277 
further explored, where aHR for the first trimester was 1.59 (95% CI 0.64-3.97), second trimester 278 
1.23 (95% CI 0.45-3.40) and with a significant association during the third trimester (aHR 2.57 279 
95% CI 1.10-6.01) (Table 3). Too few cases were available for separate analyses of exposure in 280 
different trimesters and CD/UC.  281 
Table 3. Crude and adjusted Hazard ratios and 95% confidence intervals for the association 282 
between systemic antibiotics and inflammatory bowel disease (IBD) in different trimesters during 283 
pregnancy.  284 
 285 
 286 
 287 
 288 
cHR – Crude Hazard Ratio; 3 945 000 Person-years  289 
aHR – Adjusted Hazard Ratio; 3 874 000 Person-years; analyses adjusted for mother’s and 290 
father’s history of IBD, parental education, mother’s and father’s country of birth. Those with 291 
missing information on these variables are excluded (no cases excluded). 292 
n – cases, i.e. those who have been exposed to antibiotics prior to onset of IBD293 
 IBD 
Trimester n cHR (95% CI) aHR (95% CI) 
First 5 1.59 (0.63-4.01) 1.59 (0.64-3.97) 
Second 4 1.27 (0.46-3.51) 1.23 (0.45-3.40) 
Third 6 2.60 (1.11-6.10) 2.57 (1.10-6.01) 
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Antibiotics in infantile age 294 
Table 4 presents crude and adjusted Hazard Ratios (aHR) and 95% Confidence Intervals (CI) for 295 
the association between exposure to antibiotics in infantile age and IBD, CD and UC 296 
respectively. No significant associations were found for systemic antibiotics and “PcV” for IBD, 297 
CD or UC, where aHR varied between 0.72 (95% CI 0.27-1.92) (CD), 1.23 (95% CI 0.45-3.39) 298 
(UC) and 1.11 (95% CI 0.57-2.15) (IBD) for systemic antibiotics and 0.87 (95% CI 0.33-2.27) 299 
(CD), 1.20 (95% CI 0.51-2.81) (UC) and 1.25  (95% CI 0.70-2.26) (IBD) for “PcV”. The 300 
associations remained non-significant after excluding individuals with gastroenteritis for both 301 
systemic antibiotics and “PcV” and all outcomes (IBD, CD and UC).302 
 19 
 
Table 4. Crude and adjusted Hazard ratios and 95% confidence intervals for the association between exposure to systemic antibiotics 303 
and “PcV” in infantile age and inflammatory bowel disease (IBD), and results from sensitivity analysis excluding those who had been 304 
diagnosed with gastroenteritis (GE) 12 months prior to onset of the first IBD diagnosis.  305 
 306 
cHR – Crude Hazard Ratio; 3 945 000 Person-years  307 
aHR – Adjusted Hazard Ratio; 3 874 000 Person-years; analyses adjusted for mother’s and father’s history of IBD, parental education, 308 
mother’s and father’s country of birth and mode of delivery. Those with missing information on these variables are excluded (no cases 309 
excluded). 310 
n – cases, i.e. those who have been exposed to antibiotics prior to onset of IBD/UC/CD diagnosis 311 
exl.GE – excluding gastroenteritis, either bacterial or viral, according to ICD 10 codes A00-A09 12 months prior to onset of the first 312 
IBD diagnosis. 313 
PcV – Phenoxymethylpenicillin314 
 IBD Crohn’s disease (CD) Ulcerative colitis (UC)  
Antibiotics n cHR (95% CI) aHR (95% CI) n cHR (95% CI) aHR (95% CI) n cHR (95% CI) aHR (95% CI) 
  Any 25 1.13  
(0.58-2.20) 
1.11  
(0.57-2.15) 
9 0.72  
(0.27-1.94) 
0.72 
(0.27-1.92) 
11 1.22  
(0.44-3.37) 
1.23  
(0.45-3.39) 
   exl.GE 23 1.28 
 (0.60-2.73) 
1.26 
(0.60-2.64) 
7 0.66  
(0.22-1.99) 
0.66  
(0.23-1.92) 
11 1.39  
(0.46-4.25) 
1.40  
(0.46-4.25) 
  PcV 22 1.27  
(0.70-2.31) 
1.25  
(0.70-2.26) 
8 0.88  
(0.33-2.31) 
0.87  
(0.33-2.27) 
9 1.19  
(0.50-2.80) 
1.20  
(0.51-2.81) 
   exl.GE 21 1.55  
(0.80-3.00) 
1.52  
(0.80-2.90) 
7 1.07 
(0.36-3.21) 
1.06 
(0.37-3.10) 
9 1.29  
(0.52-3.23) 
1.31  
(0.53-3.22) 
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Exploring the association between individuals who had been exposed to systemic 315 
antibiotics during the first year of life and the risk of first IBD diagnosis from 2 years of age, the 316 
aHR was 1.49 (95% CI 0.69-3.22). Furthermore, no significant interaction (p=0.48) was found 317 
between systemic antibiotics and parity and IBD, where the aHR in first-born was 0.93 (95% CI 318 
0.39-2.22) and 1.38 in non-first-borns (95% CI 0.58-3.27) (data not tabulated).  319 
No dose-response relationship was found between increasing number of 320 
prescriptions for systemic antibiotics in infantile age and IBD (Table 5). 321 
Table 5. Crude and adjusted Hazard ratios and 95% confidence intervals for inflammatory bowel 322 
disease (IBD) in relation to increasing number of antibiotic prescriptions. 323 
 324 
 325 
 326 
 327 
cHR – Crude Hazard Ratio; 3 945 000 Person-years  328 
aHR – Adjusted Hazard Ratio; 3 874 000 Person-years; analyses adjusted for mother’s and 329 
father’s history of IBD, parental education, mother’s and father’s country of birth and mode of 330 
delivery. Those with missing information on these variables are excluded (no cases excluded). 331 
n – cases, i.e. those who have been exposed to antibiotics prior to onset of IBD diagnosis 332 
 333 
334 
 IBD 
Systemic antibiotics,  
filled prescriptions 
n cHR (95% CI) aHR (95% CI) 
1 6 0.73 (0.28-1.92) 0.73 (0.28-1.89) 
2 9 1.87 (0.81-4.34) 1.85 (0.80-4.30) 
≥3 10 1.15 (0.48-2.75) 1.12 (0.47-2.65) 
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DISCUSSION 335 
In this nationwide population-based birth cohort study of more than 800 000 children, we found a 336 
positive association between antibiotics exposure during pregnancy and later VEO-IBD and CD, 337 
but not UC. The aHR seemed to remain when restricting systemic antibiotic exposure to PcV, 338 
although no longer significant for CD. The risk estimates for systemic antibiotics and CD 339 
remained similar after exclusion of children with gastroenteritis 12 months prior to their first IBD 340 
diagnosis. No association was found between systemic antibiotics or “PcV” in infantile age and 341 
later VEO-IBD, CD or UC, independent of exclusion of individuals with gastroenteritis prior to 342 
their first IBD diagnosis. This is important as gastroenteritis may have represented undiagnosed 343 
IBD, and resulted in antibiotics treatment occurring after IBD rather than preceding it. 344 
Furthermore, there was no significant association for children who had been exposed to systemic 345 
antibiotics during the first year of life and the risk of first IBD diagnosis from 2 years of age, or 346 
between increasing numbers of filled prescriptions for antibiotics and IBD.  347 
Previous literature 348 
While recent research has confirmed that antibiotic use is associated with an increased risk of 349 
IBD, including pediatric CD, less attention has been paid to VEO-IBD. In a recent meta-analysis, 350 
Ungaro et al. examined 11 studies,
31-41
 with four focusing on paediatric IBD.
34 37 39 40
 The authors 351 
regarded only three of these as paediatric,
34 37 39
 and when pooling their data the HR was 352 
substantially higher than in the overall meta-analysis (HR 2.75, 95% CI 1.72-4.38) for children 353 
only).  354 
Antibiotics may influence the risk of acquiring IBD in several ways. Firstly 355 
antibiotics may be causally related to IBD, potentially by a mediating effect on the microbiome, 356 
causing a reduced diversity and an increased dysbiosis.
42
 The microbiome interacts with the host 357 
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through production of short-chain fatty acids (including butyrate), induction of the mucosal 358 
immune system, stimulation of the local nervous system but also through interaction with the 359 
lamina propria by modification of the gut barrier function.
43
 A dysbiosis in the gut microbiota, 360 
characterized by reduction of beneficial bacteria such as Faecalibacterium prausnitzii, and 361 
Ruminococcaceae and an increase of pathogens or pathobionts, has consistently been shown in 362 
patients with IBD, especially ileal CD.
44
 Compared to previous studies we did not find any 363 
association between antibiotics treatment in infantile age and IBD, maybe due to that VEO-IBD 364 
is partly a different entity from later-onset IBD.
31 39
 On the other hand, we found a two-fold 365 
increased risk in offspring to mothers receiving antibiotics during pregnancy. We suggest such 366 
antibiotics exposure may be detrimental to the risk of VEO-IBD in the offspring. The gut 367 
microbiota in pregnant women resembles that of healthy non-pregnant women during the first 368 
two trimesters, but undergoes substantial changes during the third trimester.
45
 In our study, the 369 
highest risk of later VEO-IBD was seen in mothers exposed to antibiotics in the last trimester 370 
(aHR 2.57 95% CI 1.10-6.01), i.e. just before birth. Recent animal research indicates that 371 
antibiotics administered during pregnancy have substantial effects on the offspring microbiome 372 
(reduced bacterial diversity), but may also influence the immune response in the offspring
45
 and 373 
increase susceptibility to develop colonic inflammation.
46
  374 
While it has long been thought that the intestinal tract is sterile at birth, recent data 375 
suggest that the microbial colonization process may be initiated already in utero, 
47
a process that 376 
may be affected by antibiotics late in pregnancy. Furthermore, it has been suggested in studies of 377 
repeated fecal samples from term infants that the use of intrapartum PcV prophylaxis, to prevent 378 
early onset group B streptococcal infection in newborns, alters the offspring microbiome,
48 49
 379 
although others have found very few differences between antibiotic-exposed and non-antibiotic-380 
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exposed infants.
50
Meanwhile maternal intake of probiotics influence the expression of toll-like 381 
receptors in infant meconium,51 indicating that fetal exposure of antibiotics may play an 382 
important role for the development microbiota and the immune system of the child.
48
 While a 383 
causative association between antibiotics during pregnancy and VEO-IBD thus seems plausible, 384 
we cannot exclude possible confounding from an intrauterine infection with fever of the mother 385 
and a raised inflammatory reaction, causing epigenetic imprinting in the fetus and subsequent 386 
VEO-IBD.  Bernstein and colleagues recently suggested that individuals with IBD were no more 387 
likely than controls to have been born to mothers with peripartum infections, however they were 388 
diagnosed at an earlier age than those whose mothers did not have an infection.
52
 Unfortunately, 389 
we had no data on the indications of the mother’s antibiotic treatment during pregnancy or on 390 
either symptoms (or date of symptom onset) or genotype in patients, neither were we able to 391 
examine the microbiota per se in children with VEO-IBD 392 
 In the meta-analysis by Ungaro et al. also fluoroqinolones were highly linked to 393 
IBD (pooled OR=1.79, 95% CI 1.03-3.12).
21
 During the study period fluoroqinolones were not 394 
recommended for younger children in Sweden and only accounted for 0.2% of all antibiotic 395 
prescriptions, we therefore chose not to examine fluoroqinolone exposure and IBD separately. 396 
The fact that the highest risk estimates for IBD have previously been shown for metronidazole
21 397 
31
 and fluoroqinolones
21
 (both used in the treatment of IBD, although not currently 398 
recommended
53
) suggest that reverse causation may have been an issue in earlier studies 399 
demonstrating an positive association between antibiotics treatment and later IBD.
31 39
 We did not 400 
find any association for IBD when we restricted our analysis to antibiotics in the first year of life 401 
and our outcome to IBD onset beyond 2 years of age. That sub-analysis is similar to the analysis 402 
by Ungaro et al.
21
 limiting their dataset to studies with ≥1 year of exclusion time between 403 
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antibiotics exposure and IBD (HR 1.50, 95% CI 1.44-1.57), while we found an aHR of 1.49 with 404 
broad confidence intervals (95% CI 0.69-3.22). Reverse causation is obviously not a concern 405 
regarding the possible link between antibiotics exposure during pregnancy and risk of VEO-IBD 406 
in the offspring.  407 
Strengths and limitations 408 
The main strength of this study is the nationwide cohort, based on prospective information 409 
retrieved from high quality population-based register, thereby eliminating recall bias. In addition, 410 
we were able to carry out important sub-analyses such as exclusion of individuals with 411 
gastroenteritis prior to their first IBD diagnosis, as well as including a time window between 412 
exposure and outcome, analyses that allow us to study the potential influence by information bias. 413 
Furthermore, we were able to consider familial factors such as parental history of IBD, parents’ 414 
country of birth and socioeconomic factors including education level.  415 
We acknowledge a number of limitations. Despite our use of a nationwide register-416 
based cohort of more than 800 000 children, we could only identify 51 cases of IBD in total. 417 
Thus, the number of individuals in each subgroup (CD, UC) was quite low, which is reflected by 418 
the rather wide confidence intervals and may also be of concern in the adjusted analyses, however 419 
crude and adjusted estimates were very similar. Furthermore, we acknowledge the potential 420 
difficulties to diagnose UC in this age group, why stratification of patients into UC versus CD 421 
may not be completely accurate.  This means that even a small number of misclassified patients 422 
may have affected our conclusions, since some of the results are of borderline significance, 423 
specifically in the sensitivity analyses where we excluded individuals whose potential first 424 
episode of IBD could have been misclassified as gastroenteritis. Nevertheless, we believe that the 425 
strength of our data lies in the results seen in IBD in general, which is not dependent on 426 
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stratification into UC versus CD. Misclassification of a child’s IBD diagnosis after maternal 427 
exposure to antibiotics in pregnancy is most likely non-differential, whereas it could be 428 
differential for exposure in infantile age. The misclassification of father’s diagnoses related to 429 
maternal exposure during pregnancy and to exposure in infantile age is most likely non-430 
differential, whereas misclassification of mother’s diagnoses after exposure during pregnancy 431 
could be differential, but most likely non-differential for exposure in infantile age. A non-432 
differential misclassification of the outcome will generally bias towards the null, whereas 433 
differential misclassification could lead to both higher and lower risk estimates.  434 
Overall, the limited follow-up time of our study means that we were unable to 435 
examine the long-term effect of fetal and early life antibiotics on IBD in adulthood, which may 436 
also be one possible explanation to the low number of identified cases and lack of association 437 
between antibiotic exposure in childhood and later IBD. While a previous validation of IBD, 438 
using the same definition (requiring ≥2 diagnoses of IBD) found a positive predictive value 439 
(PPV) of 93%,
27
 we acknowledge that this PPV was calculated in a population of a much higher 440 
median age and we cannot rule out that the PPV for ≥2 IBD records in young age is different. As 441 
data from primary out-patient care are not available in the NPR, the sensitivity of our study could 442 
be lower than in real life. However, we believe that the sensitivity of IBD in the NPR is high for 443 
children as paediatric IBD patients are managed by hospital-based specialists and closely 444 
monitored with visits every three to six months.
28
 In addition, to minimize the risk of false 445 
positive cases and to increase the specificity, we used ≥2 diagnoses for our outcome, even though 446 
this could mean that we probably excluded some true cases with a lower sensitivity as result.The 447 
small number of cases also limited our possibility to perform sibling analysis, which otherwise 448 
would have helped us to control for all factors siblings share (both genetic and environmental).  449 
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Unfortunately, no population-based data on exposure to antibiotics in inpatient care 450 
are available in Sweden today. We have previously shown that 13% of vaginal deliveries are 451 
associated with intrapartum exposure to antibiotics.
54
 The corresponding number for elective 452 
caesarean section was 14%, and 63% for emergency caesarean section. Thus, while the majority 453 
of antibiotics in Sweden (87%) are prescribed in out-patient care
55
, we did not capture those 454 
exposed to antibiotics during the immediate intrapartum period, but were able to adjust for mode 455 
of delivery as a co-variate. Exposure of antibiotics was furthermore defined as having filled a 456 
prescription of antibiotics, which is not equivalent to adherence to treatment.
56
 Finally, the 457 
number of children receiving different subtypes of antibiotics was limited, wherefore we were 458 
only able to perform stratified analyses on PcV.  459 
Conclusion and implications 460 
In conclusion, we found an association between antibiotics exposure during pregnancy, 461 
specifically during the third trimester, but not in infantile age, and subsequent development of 462 
VEO-IBD. Our results may indicate that antibiotic exposure in late pregnancy can lead to 463 
changes in the microbiome of the child, however further research is needed to confirm our 464 
findings. In addition, the absolute risk of VEO-IBD is very low, and antibiotics during pregnancy 465 
should still be used when needed. 466 
 467 
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Figure legends and footnotes for figures 645 
Figure 1. A Directed Acyclic Graph (DAG) depicting the included variables in the final models. 646 
 647 
 648 
Footnote:  649 
The DAG can be applied to various analyses, for example, a study of the association between 650 
antibiotic exposure and VEO-IBD. A directed arrow between these two variables indicates that 651 
the exposure is associated with the outcome. DAGs can be used to identify all potential 652 
confounders that may exist, in order to know which variables that should be adjusted for in the 653 
analyses. When the exposure and the outcome are common causes for a third factor (a common 654 
effect), this factor is called a collider.  Pathways through colliders are closed, unless the collider 655 
is adjusted for which will then open the path and potentially cause spurious associations. In this 656 
DAG, parental education is a potential collider through parental IBD, however, with adjustment 657 
of parental IBD, this backdoor pathway is closed.  658 
* Mode of delivery was only included in analysis of antibiotic exposure in infantile age.  659 
 660 
 661 
 662 
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Figure 2. Flow chart of final study population. 664 
 665 
Footnote: 666 
*The first estimated conception date, based on date of birth and gestational age in days, is July 1, 667 
2005, and the first child in the cohort was born January 8, 2006. The last estimated conception 668 
date was July 7, 2013, and the child was born after 164 days on December 30, 2013. 669 
MBR – Medical Birth Register 670 
MGR – Multi-generation Register 671 
SPDR – Swedish Prescribed Drug Register 672 
LISA – Longitudinal integration database for health insurance and labour market studies 673 
TPR – Total Population Register 674 
 675 
 676 
